PMC9377337_01
(A) The clinical course of the patient and (B) the PSA and tumor measurements. *Two measurable liver lesions. BID, twice daily; PSA, prostate-specific antigen; Q3M, every 3 months; Q3W, every 3 weeks; QD, once daily.
fonc-12-951348-g001.jpg
PMC9377337_01_fonc-12-951348-g001.jpg
f1
The patient started the antiandrogen bicalutamide (oral) shortly after confirmed diagnosis ( Figure 1A ) and a gonadotrophin-releasing hormone agonist, leuprorelin (depot injection), was subsequently initiated to affect androgen deprivation. The patient started at the recommended dose of rucaparib, 600 mg twice daily, but the dose was reduced to 500 mg twice daily due to nausea/fatigue, with the patient ultimately receiving rucaparib for 32 weeks ( Figure 1A ). Tumors, version 1.1 (51% decrease in liver metastasis target lesion diameters;  Figure 1B ) lasting 13 weeks, ongoing as of the last radiographic assessment before subsequent anti-cancer therapy, resulting in a rPFS of 29 weeks, with no confirmed progression in bone. The patient also had a confirmed PSA response (maximum decrease, 95%;  Figure 1B ) lasting 28 weeks from the first dose of rucaparib. The patient discontinued rucaparib treatment due to clinical disease progression after 32 weeks on study and subsequently received palliative radiotherapy due to painful bone lesions.